Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Conference Call May 6, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief Executive Officer Nick Pizzie - Chief Financial Officer Ari Maizel - Executive Vice President & Head, Commercial Mark Jacobson - Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Leonid Timashev - RBC Capital Markets Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Marc Goodman - L ...

Exhibit 99.1 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q 2024 net product revenue of $21.6 million representing 64% year-over-year growth Contract executed with second large group purchasing organization (GPO) for potential coverage of Auvelity Positive pivotal Pha ...

Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine. But not all biotech companies are the same. Some are established pharmaceutical giants while others are pre-revenue startups that are banking on a drug breakthrough. What this means is that an FDA approval or denial can have major consequences on the stock. If you want to invest in biotech stocks, you will need to keep up ...

The market expects Axsome Therapeutics (AXSM) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 6, 2024, might help the stock move higher if these key numbers ar ...

AXS-05 in Alzheimer's disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative psychiatry and ...

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome's management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and provide a bus ...

Axsome Therapeutics, Inc. (AXSM) announced that it has initiated the phase III ENGAGE study evaluating its investigational therapy, solriamfetol, for treating adult patients with binge eating disorder (BED).Solriamfetol is presently marketed in the United States under the brand name Sunosi for the treatment of narcolepsy.The double-blind, placebo-controlled phase III study will evaluate the safety and efficacy of solriamfetol (150 mg or 300 mg) in adult patients with BED. The primary endpoint of the study i ...

Group 1: Axsome Therapeutics - Axsome Therapeutics has a market cap of $3.7 billion, which is considered low compared to its growth potential due to its late-stage pipeline [2] - The company’s approved product, Auvelity, is being tested for treating Alzheimer's disease agitation, with the number of Alzheimer's patients in the U.S. projected to rise from 6.7 million to 14 million by 2060 [2] - Axsome Therapeutics could have five marketed products by the end of next year, indicating substantial upside potential [3] Group 2: CRISPR Therapeutics - The global gene-therapy market is expected to grow at a CAGR of 19.5% until the end of the decade, making CRISPR Therapeutics a potentially lucrative investment [4] - CRISPR Therapeutics has an approved gene-therapy treatment, Casgevy, which is considered cost-effective despite its high price of over $2 million [4] - The approval of Casgevy for treating sickle cell disease and beta-thalassemia is expected to strengthen CRISPR's financials and open up significant growth opportunities [5] Group 3: Pfizer - Pfizer has a low price-to-earnings-to-growth (PEG) ratio of 0.27, indicating an attractive valuation [6] - The company projects annual revenue of $25 billion by 2030 from new product launches, which will offset an estimated $17 billion in lost revenue from expiring patents [7] - Pfizer expects a CAGR of around 10% in revenue growth between 2025 and 2030, alongside a dividend yield of over 6% [8]

A month has gone by since the last earnings report for Axsome Therapeutics (AXSM) . Shares have lost about 4% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Axsome’s Q4 Earnings & Revenue Surpass EstimatesA ...

Axsome Therapeutics, Inc. (AXSM) announced that it has dosed the first patient in the phase III PARADIGM study evaluating its investigational therapy, solriamfetol, for treating major depressive disorder (MDD). Shares of the company were up 6% on Mar 19, following the announcement of the news.Solriamfetol is marketed in the United States under the trade name, Sunosi, for the treatment of narcolepsy.The double-blind and placebo-controlled phase III study will evaluate the safety and efficacy of solriamfetol ...